Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Haemonetics Corporation Common Stock (NY: HAE )

65.48 +0.55 (+0.85%)
Streaming Delayed Price Updated: 10:01 AM EST, Feb 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 Next >
(HAE) - Analyzing Haemonetics's Short Interest
Via Benzinga
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect
Eyecare company Bausch + Lomb (NYSE:BLCO) will be announcing earnings results tomorrow morning. Here’s what to expect. 
Via StockStory
Inspire Medical Systems (INSP) To Report Earnings Tomorrow: Here Is What To Expect
Medical technology company Inspire Medical Systems (NYSE:INSP) will be reporting results tomorrow after market close. Here’s what you need to know. 
Via StockStory
Haemonetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
For those who appreciate value investing, NYSE:HAE is a compelling option with its solid fundamentals.
HAEMONETICS CORP/MASS is a hidden gem, featuring undervaluation and robust fundamentals. NYSE:HAE showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
Haemonetics (NYSE:HAE) Misses Q4 Revenue Estimates
Blood products company Haemonetics (NYSE:HAE). fell short of the market’s revenue expectations in Q4 CY2024 as sales rose 3.7% year on year to $348.5 million. Its non-GAAP profit of $1.19 per share was... 
Via StockStory
Earnings Scheduled For February 6, 2025
Via Benzinga
How Is The Market Feeling About Haemonetics?
Via Benzinga
The Latest Analyst Ratings For Haemonetics
Via Benzinga
Earnings To Watch: Haemonetics (HAE) Reports Q4 Results Tomorrow
Blood products company Haemonetics (NYSE:HAE). will be announcing earnings results tomorrow before the bell. Here’s what to expect. 
Via StockStory
While growth is established for NYSE:HAE, the stock's valuation remains reasonable.
For those who appreciate growth without the sticker shock, HAEMONETICS CORP/MASS (NYSE:HAE) is worth considering. 
Via Chartmill
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering.
In the world of growth stocks, NYSE:HAE shines as a value proposition. 
Via Chartmill
Deep Dive Into Haemonetics Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
NYSE:HAE is not too expensive for the growth it is showing.
While growth is established for NYSE:HAE, the stock's valuation remains reasonable. 
Via Chartmill
Despite its growth, NYSE:HAE remains within the realm of affordability.
HAEMONETICS CORP/MASS (NYSE:HAE), a growth stock which is not overvalued. 
Via Chartmill
What Analysts Are Saying About Haemonetics Stock
Via Benzinga
Investors should take note of NYSE:HAE, a growth stock that remains attractively priced.
Looking for growth without the hefty price tag? Consider NYSE:HAE. 
Via Chartmill
NYSE:HAE stands out as a growth opportunity that won't break the bank.
Investors should take note ofHAEMONETICS CORP/MASS (NYSE:HAE), a growth stock that remains attractively priced. 
Via Chartmill
Analyst Expectations For Haemonetics's Future
Via Benzinga
Top 3 Health Care Stocks That Are Set To Fly This Quarter
Via Benzinga
Investors should take note of NYSE:HAE, a growth stock that remains attractively priced.
Investors seeking growth at a reasonable cost should explore HAEMONETICS CORP/MASS (NYSE:HAE). 
Via Chartmill
NYSE:HAE stands out as a growth opportunity that won't break the bank.
NYSE:HAE is not too expensive for the growth it is showing. 
Via Chartmill
Looking for growth without the hefty price tag? Consider NYSE:HAE.
HAEMONETICS CORP/MASS (NYSE:HAE) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst
Analyst upgrades Haemonetics to Buy, believes company can reach high-20% operating margin goal by FY26 through product mix analysis. Price target set at $112. 
Via Benzinga
NYSE:HAE, a growth stock which is not overvalued.
Despite its growth, HAEMONETICS CORP/MASS (NYSE:HAE) remains within the realm of affordability. 
Via Chartmill
4 Analysts Assess Haemonetics: What You Need To Know
Via Benzinga
This McCormick Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
These 3 Companies Boast Bright Outlooks
Favorable earnings estimate revisions are key for a stock to move higher. Let’s examine a few highly ranked stocks, including Stride, Interactive Brokers, and Haemonetics. 
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.